The groundbreaking success of Viagra undeniably reshaped the pharmaceutical landscape, but betting in companies primarily reliant on generic versions presents a challenging picture. Although early profits were impressive, the end of patents and the rise of cheaper alternatives have weakened sales. Thus, a thorough analysis of ongoing income sources